Entera Bio Ltd.

For the period ended Dec 31, 2024. Filed Mar 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 28, 2025

ENTX$3.25+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Shareholders' Equity

CHANGES IN SHAREHOLDERS' EQUITY

(U.S. dollars in thousands, except share and per share data)

	Ordinary shares
Number of shares issued · Amounts · Additional paid-in capital · Accumulated other Comprehensive income · Accumulated deficit · Total
BALANCE AT JANUARY 1, 2023	28,809,922	*	107,210		41	(95,497)	11,754
Net loss	-	-	-		-	(8,889)	(8,889)
Issuance of ordinary shares, warrants and pre-funded warrants in a private placement, net of issuance costs	6,662,389	1	5,826		-	-	5,827
Issuance of shares under the ATM program, net of issuance costs	4,030	*	5		-	-	5
Share-based compensation	-	-	1,689		-	-	1,689
BALANCE AT DECEMBER 31, 2023	35,476,341	1	114,730		41	(104,386)	10,386
Net loss	-	-	-		-	(9,541)	(9,541)
Exercise of warrants to ordinary shares	89,820	*	90		-	-	90
Exercise of options to ordinary shares	733,704	*	749		-	-	749
Issuance of shares under the ATM program, net of issuance costs	2,236,126	*	3,840		-	-	3,840
Vested restricted share units	301,229	*	(*	)	-	-	-
Share-based compensation	-	-	2,556		-	-	2,556
BALANCE AT DECEMBER 31, 2024	38,837,220	1	121,965		41	(113,927)	8,080

Represents an amount less than one thousand U.S. dollars.

The accompanying notes are an integral part of these consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.